Market Challenges And Opportunities

Global Polyclonal Antibody Market Drivers

Increasing product launch: Increasing adoption of inorganic growth strategies, such as product launch by key market players is expected to drive the global polyclonal antibody market over the forecast period. For instance, in February 2023, F. Hoffmann-La Roche Ltd., a pharmaceutical company, announced the launch of the IDH1 R132H (MRQ-67) Rabbit Monoclonal Primary Antibody and the ATRX Rabbit Polyclonal Antibody to identify mutation status in patients diagnosed with brain cancer.
Partnerships among key market players: Increasing adoption of inorganic growth strategies, such as partnership is expected to drive the global polyclonal antibody market over the forecast period. For instance, in March 2020, GigaGen Inc., a biotechnology company in U.S., announced the development of a recombinant polyclonal antibody therapy for the treatment of COVID-19.

Global Polyclonal Antibody Market Opportunities

Growing applications of polyclonal antibodies in diagnostics: The growing applications of polyclonal antibodies in diagnostics are having a significant impact on the global polyclonal antibody market. Polyclonal antibodies are seeing increased use in diagnosing a wide range of medical conditions due to their ability to bind to multiple epitopes on an antigen. This allows them to detect antigens more sensitively and accurately compared to monoclonal antibodies. Their multi-specificity also enables them to detect various conformational changes or modifications in antigens. For instance, polyclonal antibodies are indispensable in ELISA-based testing for conditions like rheumatoid arthritis, hepatitis, influenza and COVID-19. The pandemic has driven up the demand tremendously as polyclonal form the core of many serology tests used for detecting COVID-19 antibodies.
Adoption of recombinant polyclonal antibodies: The adoption of recombinant polyclonal antibodies is having a significant impact on the global polyclonal antibody market. Recombinant technology allows for polyclonal antibodies to be produced more consistently and reliably than traditional production methods. Using recombinant techniques, antibodies can be created by isolating antibody-producing immune cell sequences and introducing them into host cells that can mass produce the antibodies. This provides a standardized and scalable method for generating polyclonal antibodies without needing to immunize animals.

Restraints & Challenges:

The high costs associated with polyclonal antibody production
Stringent Regulations

Global Polyclonal Antibody Market Restraints

The high costs associated with polyclonal antibody production : The high costs associated with polyclonal antibody production pose a significant challenge for the growth of the global polyclonal antibody market. Polyclonal antibodies are produced by inoculating an animal with an antigen, which stimulates the immune system of the animal to produce a diverse range of antibodies against that target antigen. For instance, the average costs of setting up and operating animal housing and healthcare facilities ranged from US$ 0.5-1 million annually for most mid-sized producers in 2020. Collectively, these expenses pose inhibitive entry barriers for new players and restrain the potential growth of the polyclonal antibody market, especially in low and middle-income countries.

Counterbalance: Thus, key market players are focused on meeting these regulatory standards, which further drives up production expenses.

Stringent regulations

Stringent regulations across various countries are indeed restraining the growth of the global polyclonal antibody market to a large extent. Polyclonal antibodies are produced in animals via immunization and hence involve animal testing and experimentation. Many nations have stringent laws in place to curb excessive and unnecessary animal testing in research.